ST PHARM CO., LTD.
ST Pharm operates a top-3 global oligonucleotide CDMO and develops in-house drug candidates including the HIV treatment STP0404.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2008, ST Pharm listed on KOSDAQ in 2016 as an API and CDMO company. It holds the No.1 position in Asia and a top-3 global position in oligonucleotide (RNA therapeutic raw material) CDMO, also operates small-molecule CDMO and generic CMO businesses, and is the only global CDMO to hold US FDA cGMP certification in both small-molecule (2018) and oligonucleotide (2022) API manufacturing. Its in-house pipeline includes the first-in-class HIV treatment STP0404 (Pirmitegravir, in US Phase 2a trials) and the anticancer drug STP1002 (Basroparib, Phase 1 completed) for advanced solid tumors, and it has signed a KRW 17.7 billion LNP lipid supply agreement with a North American mRNA drug developer (2022) and a strategic partnership with Germany's Evonik Industries (2025).
Products & technology
- Oligonucleotide APICDMO for RNA therapeutic raw material
- Small-molecule API CDMOContract development and manufacturing of small-molecule APIs
- Generic CMOContract manufacturing for generics
- sgRNA raw materialCDMO for CRISPR-Cas9-related gene editing raw materials
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2022 (Phase 1 1)
- Phase 1STP2104 주2022-03-24
8 trial sites
R&D and key agreements
Source: DART corporate disclosureSTP0404(Pirmitegravir) · 에이즈(HIV) 치료제 · 미국 임상 2a상 진행 중(프랑스 임상1상 완료) · First-in-class drug in its class to enter human trials. Cohort 1/2 interim results presented at IDWeek in Oct. 2025; final Phase 2a data including cohort 3 planned for 2026
STP1002(Basroparib) · 대장암, 비소세포폐암, 간암 등 진행성고형암 · 임상1상 완료 · First-in-class anticancer drug; Phase 1 results disclosed Sep. 2024 showing safety, presented at ESMO Congress 2024 (Sep 13-17, 2024)
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition